vs
Side-by-side financial comparison of Borealis Foods Inc. (BRLS) and Citius Pharmaceuticals, Inc. (CTXR). Click either name above to swap in a different company.
Borealis Foods Inc. is the larger business by last-quarter revenue ($7.1M vs $3.9M, roughly 1.8× Citius Pharmaceuticals, Inc.). Borealis Foods Inc. runs the higher net margin — -53.2% vs -238.2%, a 185.0% gap on every dollar of revenue.
Borealis Foods Inc is a food technology enterprise specializing in developing and producing high-quality plant-based protein products including plant-based meat alternatives. It mainly serves retail and food service customers across North America and Europe, focusing on delivering affordable, nutritious sustainable food options matching the taste of conventional animal-derived meat.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
BRLS vs CTXR — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $3.9M |
| Net Profit | $-3.8M | $-9.4M |
| Gross Margin | 14.6% | 80.0% |
| Operating Margin | -27.1% | -228.7% |
| Net Margin | -53.2% | -238.2% |
| Revenue YoY | -12.0% | — |
| Net Profit YoY | 21.8% | 8.6% |
| EPS (diluted) | $-0.18 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.9M | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $7.2M | — | ||
| Q1 25 | $6.8M | — | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $8.1M | — | ||
| Q2 24 | $5.5M | — | ||
| Q1 24 | $7.9M | — |
| Q4 25 | — | $-9.4M | ||
| Q3 25 | $-3.8M | — | ||
| Q2 25 | $-4.6M | — | ||
| Q1 25 | $-4.2M | — | ||
| Q4 24 | $-5.8M | — | ||
| Q3 24 | $-4.8M | — | ||
| Q2 24 | $-6.3M | — | ||
| Q1 24 | $-8.4M | — |
| Q4 25 | — | 80.0% | ||
| Q3 25 | 14.6% | — | ||
| Q2 25 | 7.2% | — | ||
| Q1 25 | 13.1% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 7.7% | — | ||
| Q1 24 | 3.1% | — |
| Q4 25 | — | -228.7% | ||
| Q3 25 | -27.1% | — | ||
| Q2 25 | -46.7% | — | ||
| Q1 25 | -42.6% | — | ||
| Q4 24 | -68.4% | — | ||
| Q3 24 | -44.8% | — | ||
| Q2 24 | -94.8% | — | ||
| Q1 24 | -88.3% | — |
| Q4 25 | — | -238.2% | ||
| Q3 25 | -53.2% | — | ||
| Q2 25 | -64.0% | — | ||
| Q1 25 | -61.2% | — | ||
| Q4 24 | -85.3% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -115.0% | — | ||
| Q1 24 | -106.8% | — |
| Q4 25 | — | $-0.38 | ||
| Q3 25 | $-0.18 | — | ||
| Q2 25 | $0.21 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.82 | — | ||
| Q3 24 | $-0.23 | — | ||
| Q2 24 | $0.29 | — | ||
| Q1 24 | $-0.49 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $7.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-12.9M | $80.0M |
| Total Assets | $56.3M | $140.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $80.0M | ||
| Q3 25 | $-12.9M | — | ||
| Q2 25 | $-9.2M | — | ||
| Q1 25 | $-4.8M | — | ||
| Q4 24 | $-695.9K | — | ||
| Q3 24 | $5.1M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $16.2M | — |
| Q4 25 | — | $140.4M | ||
| Q3 25 | $56.3M | — | ||
| Q2 25 | $57.3M | — | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $60.0M | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $63.6M | — | ||
| Q1 24 | $70.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-190.6K | $-13.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-13.0M | ||
| Q3 25 | $-190.6K | — | ||
| Q2 25 | $-2.2M | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-819.4K | — | ||
| Q3 24 | $-3.3M | — | ||
| Q2 24 | $-4.2M | — | ||
| Q1 24 | $-6.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-951.6K | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-4.7M | — | ||
| Q1 24 | $-7.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -20.3% | — | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -46.1% | — | ||
| Q2 24 | -86.7% | — | ||
| Q1 24 | -92.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 5.6% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 7.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
